BIH Lecture | Thomas Kaiser "Transparency Matters: A Tale of 1000 and 1 Drug Assessments"

How does the AMNOG process ensure greater transparency in drug evaluation? Learn why full disclosure of manufacturer data is crucial and how the upcoming European Health Technology Assessment (EU-HTA) will shape the future of drug evaluation.
BIH Lecture
"Transparency Matters: A Tale of 1000 and 1 Drug Assessments"
In 2011, Germany implemented a systematic drug assessment process called AMNOG. Transparency is key to AMNOG: All data must be submitted by the manufacturer and the assessment is published in full. This talk will illustrate why this matters and provide a perspective on the forthcoming European benefit assessment (EU-HTA).
About the Speaker
Thomas Kaiser
Director of the Institute for Quality and Efficiency in Health Care (IQWiG).
Physician and System Developer. Co-founder of the German Institute for Evidence-based Medicine (DIeM), Cologne, in 2002. From the founding of the Institute for Quality and Efficiency in Health Care (IQWiG) in 2004 until 2023: Head of the Drug Assessment Department. Director of IQWiG since 1 April 2023. Recipient of the Bill Silverman Prize of the Cochrane Collaboration (together with 3 other IQWiG staff members) in 2008. Recipient of the David Sackett Prize of the German Network for Evidence-based Medicine (DNebM) in 2011 (prize awarded to IQWiG‘s Drug Assessment Department).
Info
When
December 4, 2026
12:00 - 1:00 pm
Where
Online via Zoom
>> The login link will be provided shortly before the event.
Registration
Please register here.
